Dr. Yurong Lai, Ph. D - Bristol-Myers Squibb

Dr. Yurong Lai

Ph. D

Bristol-Myers Squibb

Princeton, NJ | United States

Main Specialties: Other

Additional Specialties: Transporter protein

Dr. Yurong Lai, Ph. D - Bristol-Myers Squibb

Dr. Yurong Lai

Ph. D

Introduction

Primary Affiliation: Bristol-Myers Squibb - Princeton, NJ , United States

Specialties:

Additional Specialties:

Publications

74Publications

4085Reads

2Profile Views

642PubMed Central Citations

Organic Anion Transporter 2: An Enigmatic Human Solute Carrier.

Drug Metab Dispos 2017 02 21;45(2):228-236. Epub 2016 Nov 21.

Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Research and Development, Princeton, New Jersey (H.S., Y.L.), and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer World Wide Research and Development, Groton, Connecticut (A.D.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.116.072264DOI Listing
February 2017
16 Reads
3 Citations
3.252 Impact Factor

Disrupted Murine Gut-to-Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models.

J Pharmacol Exp Ther 2017 Jan 27;360(1):174-191. Epub 2016 Oct 27.

Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada (E.C.Y.C., H.P.Q., J.Z.Y.W., K.S.P.); Bristol Myers Squibb, Pharmaceutical Candidate Optimization Department, Princeton, New Jersey (Y.Z., Y.L.); Pharmacokinetics, Dynamics, and Metabolism, Janssen Research and Development, LLC, Spring House, Pennsylvania (D.C.E., J.S.); In Vitro ADMET Laboratories, Columbia, Maryland (A.P.L.); Department of Physiology and Pharmacology and Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (R.G.T.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.116.236935DOI Listing
January 2017
57 Reads
1 Citation
3.972 Impact Factor

Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.

Drug Metab Dispos 2016 11 19;44(11):1752-1758. Epub 2016 Aug 19.

Department of Pharmaceutics, University of Washington, Seattle, Washington (L.W., C.C., E.J.K., J.D.U.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck & Co., Rahway, New Jersey (X.C.); Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Gilead Sciences, Inc., Foster City, California (A.S.R., A.M.); Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California (L.S., C.E.C.A.H.); Preclinical PK and In Vitro ADME, Biogen, Cambridge, Massachusetts (G.X.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Ardea Biosciences, Inc., San Diego, California (C.L.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (Y.L.,W.H.); Takeda Pharmaceuticals International Co., Cambridge, Massachusetts (M.L.); Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck & Co., Kenilworth, New Jersey (R.E.); Department of Surgery, University of Kansas Medical Center, Kansas City, Kansas (S.C.K.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.116.071050DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074470PMC
November 2016
74 Reads
8 Citations
3.252 Impact Factor

Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.

J Pharmacol Exp Ther 2016 Sep 17;358(3):397-404. Epub 2016 Jun 17.

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (Y.L., H.S., R.L., Y.C., P.S., J.D., W.G.H., P.M.); Bristol-Myers Squibb India Pvt. Ltd., Biocon Bristol-Myers Squibb Research and Development Center, Bangalore, India (Sa.M.); and Biocon BMS R&D Center, Syngene International Ltd., Bangalore, India (V.K.H., P.R., Se.M., N.G., S.S., O.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.116.234914DOI Listing
September 2016
69 Reads
5 Citations
3.972 Impact Factor

Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment.

Biopharm Drug Dispos 2016 Jul;37(5):276-86

Pharmaceutical Candidate Optimization, Research and Development Bristol-Myers Squibb, Princeton, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bdd.2011DOI Listing
July 2016
95 Reads
1 Citation
2.180 Impact Factor

Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.

J Pharmacol Exp Ther 2016 May 23;357(2):382-93. Epub 2016 Feb 23.

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.116.232066DOI Listing
May 2016
48 Reads
2 Citations
3.972 Impact Factor

Disruption of BSEP Function in HepaRG Cells Alters Bile Acid Disposition and Is a Susceptive Factor to Drug-Induced Cholestatic Injury.

Mol Pharm 2016 Apr 8;13(4):1206-16. Epub 2016 Mar 8.

Life Science and Technology Center, Sigma-Aldrich , St. Louis, Missouri 63103, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.5b00659DOI Listing
April 2016
37 Reads
4 Citations
4.384 Impact Factor

Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach.

Drug Metab Dispos 2016 Apr 3;44(4):505-16. Epub 2016 Feb 3.

Department of Pharmacy (A.V., A.M., E.K.K., M.K., P.A.), Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Uppsala University (M.C.K.), and Uppsala University Drug Optimization and Pharmaceutical Profiling Platform, Chemical Biology Consortium, Science for Life Laboratory (P.A.), Uppsala, Sweden; and Bristol-Myers Squibb, Princeton, New Jersey (Y.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.066746DOI Listing
April 2016
46 Reads
5 Citations
3.252 Impact Factor

Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development.

Chem Res Toxicol 2016 Apr 8;29(4):545-63. Epub 2016 Mar 8.

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company , 3551 Lawrenceville Road, Princeton, New Jersey 08540, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.chemrestox.5b00511DOI Listing
April 2016
72 Reads
1 Citation
3.530 Impact Factor

Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro.

Drug Metab Dispos 2016 Mar 29;44(3):320-8. Epub 2015 Dec 29.

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.066944DOI Listing
March 2016
59 Reads
5 Citations
3.252 Impact Factor

Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation.

Drug Metab Dispos 2016 Feb 25;44(2):238-49. Epub 2015 Nov 25.

Department of Metabolism and Pharmacokinetics (H.S., T.L., X.Q., C.C., R.M.F., A.D.R., P.M., Y.L.) and Department of Bioanalytical Sciences (H.J., C.T., K.T., H.K., J.Z.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; Department of Genomic Technologies (K.K.) and Department of Genome Biology (G.M.), Bristol-Myers Squibb Research and Development, Pennington, New Jersey; and Department of Molecular Biology (S.S., P.K.), Bristol-Myers Squibb Biocon R&D Center, Bangalore, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.066852DOI Listing
February 2016
137 Reads
1 Citation
3.252 Impact Factor

Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide.

Mol Pharm 2015 Nov 30;12(11):3943-52. Epub 2015 Sep 30.

Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development , Groton, Connecticut 06340, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.5b00411DOI Listing
November 2015
39 Reads
4 Citations
4.384 Impact Factor

Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake.

Drug Metab Dispos 2015 Nov 4;43(11):1788-94. Epub 2015 Sep 4.

Pharmaceutical Candidate Optimization (B.L.M., H.C., L.Z., Y.Z., X.G., H.S., E.A.D., H.S., C.E.L., P.M., Y-Z.S., W.G.H., Y.L.) and Veterinary Sciences, Bristol-Myers Squibb, Princeton, New Jersey (J.G.M., M.F.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.065946DOI Listing
November 2015
60 Reads
3.252 Impact Factor

Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression.

Drug Metab Dispos 2015 Jul 22;43(7):984-93. Epub 2015 Apr 22.

Departments of Metabolism and Pharmacokinetics (H.S., T.L., B.L.M., Yuep.Z., X.Q., C.C., P.M., Y.L.), Bioanalytical Sciences (Y.Z., G.L.), Oncology Translational Research (A.C.L., X.-T.W.), and Biotransformation (L.J.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.114.062364DOI Listing
July 2015
100 Reads
6 Citations
3.252 Impact Factor

Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeys.

J Pharmacol Exp Ther 2015 May 4;353(2):380-91. Epub 2015 Mar 4.

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People's Republic of China (L.L.).

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/content/353/2/380.full.pdf
Web Search
http://jpet.aspetjournals.org/cgi/doi/10.1124/jpet.114.22180
Publisher Site
http://dx.doi.org/10.1124/jpet.114.221804DOI Listing
May 2015
47 Reads
2 Citations
3.972 Impact Factor

Beyond the ITC White Paper: emerging sciences in drug transporters and opportunities for drug development.

Curr Pharm Des 2014 ;20(10):1577-94

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ 08543.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/13816128113199990467DOI Listing
November 2014
52 Reads
4 Citations
3.452 Impact Factor

Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine.

Mol Pharm 2014 Oct 11;11(10):3547-55. Epub 2014 Sep 11.

Department of Experimental and Clinical Pharmacology, Pomeranian Medical University , Szczecin, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/mp500330yDOI Listing
October 2014
64 Reads
24 Citations
4.384 Impact Factor

Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions.

Drug Metab Dispos 2014 Jul 5;42(7):1210-8. Epub 2014 May 5.

Department of Pharmacy, Uppsala University, Uppsala, Sweden (A.V., M.K., E.K.S., P.A.); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Chemical Biology Consortium Sweden (M.K., P.A.), Uppsala, Sweden; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (J.R.W.); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut (Y.L.); and Department of Surgery, Uppsala University, Uppsala, Sweden (A.N.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.113.056309DOI Listing
July 2014
87 Reads
10 Citations
3.252 Impact Factor

Quantitative targeted proteomics for membrane transporter proteins: method and application.

AAPS J 2014 Jul 15;16(4):714-26. Epub 2014 May 15.

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-014-9607-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070247PMC
July 2014
28 Reads
7 Citations
3.800 Impact Factor

Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer.

AAPS J 2014 Jul 23;16(4):802-9. Epub 2014 May 23.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts, 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-014-9616-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070250PMC
July 2014
50 Reads
3.800 Impact Factor

Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump.

Drug Metab Dispos 2014 Apr 10;42(4):566-74. Epub 2013 Oct 10.

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (A.D.R., Y.L.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Wallingford, Connecticut (M.S.); Leads Discovery and Optimization, Bristol-Myers Squibb, Princeton, New Jersey (M.E.C.); and Leads Discovery and Optimization, Bristol-Myers Squibb, Wallingford, Connecticut (L.E., T.Z.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.113.054205DOI Listing
April 2014
50 Reads
11 Citations
3.252 Impact Factor

A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development.

Drug Metab Dispos 2013 Dec 24;41(12):1975-93. Epub 2013 Sep 24.

Pfizer Inc., Groton, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.113.054031DOI Listing
December 2013
43 Reads
11 Citations
3.252 Impact Factor

Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.

Biopharm Drug Dispos 2013 Nov 3;34(8):452-61. Epub 2013 Oct 3.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bdd.1861DOI Listing
November 2013
33 Reads
8 Citations
2.180 Impact Factor

Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes.

J Pharm Sci 2013 Sep 8;102(9):3252-63. Epub 2013 May 8.

Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research & Development, Groton Laboratories, Pfizer Inc., Groton, Connecticut 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.23582DOI Listing
September 2013
9 Reads
9 Citations
2.590 Impact Factor

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.

Drug Metab Dispos 2013 May 7;41(5):966-74. Epub 2013 Feb 7.

Department of Pharmacokinetics, Dynamics, and Metabolism, MS 8220-2451, Pfizer World Wide Research and Development, Pfizer Inc., Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.112.050583DOI Listing
May 2013
168 Reads
7 Citations
3.252 Impact Factor

Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.

Pharm Res 2013 Apr 10;30(4):1188-99. Epub 2013 Jan 10.

Pharmacokinetcis, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-012-0956-5DOI Listing
April 2013
47 Reads
11 Citations
3.420 Impact Factor

Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Expert Opin Drug Metab Toxicol 2013 Apr 21;9(4):459-72. Epub 2013 Jan 21.

Pfizer Worldwide Research and Development, Department of Pharmacokinetics, Dynamics and Metabolism, Eastern Point Road, Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2013.759210DOI Listing
April 2013
56 Reads
8 Citations
2.831 Impact Factor

Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma.

Hepatology 2013 Apr 15;57(4):1530-41. Epub 2013 Feb 15.

Department of Biomedical and Pharmaceutical Sciences, Center for Pharmacogenomics and Molecular Therapy, College of Pharmacy, University of Rhode Island, 41 Lower College Road, Kingston, RI 02881, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.26187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608797PMC
April 2013
23 Reads
16 Citations
11.055 Impact Factor

Inhibition of hepatobiliary transporters by a novel kinase inhibitor contributes to hepatotoxicity in beagle dogs.

Drug Metab Lett 2013 Mar;7(1):15-22

Drug Metabolism and Pharmacokinetics, Vanderbilt Center for Neuroscience Drug Discovery, Dept. of Pharmacology, Vanderbilt University Medical School, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/18723128112066660018DOI Listing
March 2013
31 Reads
4 Citations

Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype.

J Pharm Sci 2013 Mar 1;102(3):787-93. Epub 2013 Jan 1.

Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.23436DOI Listing
March 2013
40 Reads
29 Citations
2.590 Impact Factor

Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes.

Mol Pharm 2012 Dec 2;9(12):3535-42. Epub 2012 Nov 2.

Pfizer Global Research and Development, Department of Pharmacokinetics, Dynamics, and Metabolism, Groton, Connecticut 06340, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/mp300379qDOI Listing
December 2012
38 Reads
13 Citations
4.384 Impact Factor

Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.

Pharm Res 2012 Oct 26;29(10):2860-73. Epub 2012 May 26.

Pharmacokinetcis, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-012-0792-7DOI Listing
October 2012
63 Reads
15 Citations
3.420 Impact Factor

A novel relay method for determining low-clearance values.

Drug Metab Dispos 2012 Sep 29;40(9):1860-5. Epub 2012 May 29.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.112.046425DOI Listing
September 2012
59 Reads
7 Citations
3.252 Impact Factor

Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion.

Drug Metab Dispos 2012 Aug 11;40(8):1527-37. Epub 2012 May 11.

Department of Pharmacokinetics, Dynamics, and Metabolism, MS 8220-2451, Pfizer World Wide Research and Development, Pfizer, Inc., Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.112.044628DOI Listing
August 2012
52 Reads
4 Citations
3.252 Impact Factor

In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.

Drug Metab Dispos 2012 Jun 1;40(6):1085-92. Epub 2012 Mar 1.

Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer, Inc., Mailstop 8220-2475, Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.111.043489DOI Listing
June 2012
60 Reads
10 Citations
3.252 Impact Factor

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.

Expert Opin Drug Metab Toxicol 2012 Jun 18;8(6):723-43. Epub 2012 Apr 18.

Pfizer Worldwide Research and Development, Department of Pharmacokinetics, Dynamics and Metabolism, Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2012.678048DOI Listing
June 2012
87 Reads
8 Citations
2.831 Impact Factor

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Drug Metab Dispos 2012 May 16;40(5):1007-17. Epub 2012 Feb 16.

Pfizer Worldwide R&D, Department of Pharmacokinetics, Dynamics and Metabolism, Sandwich, Kent, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.111.042994DOI Listing
May 2012
42 Reads
25 Citations
3.252 Impact Factor

Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

J Med Chem 2012 May 15;55(10):4740-63. Epub 2012 May 15.

Department of Pharmacy, Uppsala University, 751 23 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm300212sDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361267PMC
May 2012
36 Reads
34 Citations
5.450 Impact Factor

Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.

Drug Metab Dispos 2012 May 8;40(5):852-5. Epub 2012 Feb 8.

Department of Pharmaceutics, University of Washington, P.O. Box 357610, Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.111.043810DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336801PMC
May 2012
82 Reads
20 Citations
3.252 Impact Factor

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.

Xenobiotica 2012 Jan 11;42(1):28-45. Epub 2011 Nov 11.

Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Sandwich, Kent, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/00498254.2011.626464DOI Listing
January 2012
199 Reads
6 Citations
2.200 Impact Factor

Development of a new permeability assay using low-efflux MDCKII cells.

J Pharm Sci 2011 Nov 15;100(11):4974-85. Epub 2011 Jul 15.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.22674DOI Listing
November 2011
71 Reads
30 Citations
2.590 Impact Factor

Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples.

Rapid Commun Mass Spectrom 2011 Jun;25(12):1715-24

Pharmacokinetics, Dynamics & Metabolism, Pfizer Global Research & Development Groton Laboratories, Pfizer Inc., Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcm.5026DOI Listing
June 2011
45 Reads
7 Citations
2.253 Impact Factor

Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogs.

Drug Metab Dispos 2011 May 14;39(5):789-95. Epub 2011 Feb 14.

Pfizer Animal Health, Metabolism & Safety, 333 Portage St., Kalamazoo, MI 49001, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.110.034827DOI Listing
May 2011
119 Reads
10 Citations
3.252 Impact Factor

Two branched polar groups and polar linker moieties of thiophene amide derivatives are essential for MRP2/ABCC2 recognition.

Drug Metab Lett 2010 Dec;4(4):254-61

Pfizer, Inc., Eastern Point Road, Groton, CT 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187231210792928215DOI Listing
December 2010
15 Reads

Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}.

J Biol Chem 2010 Oct 11;285(41):31185-92. Epub 2010 Aug 11.

From the Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc., Groton, Connecticut 06340.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M110.107805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951192PMC
October 2010
30 Reads
7 Citations
4.573 Impact Factor

Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes.

Drug Metab Dispos 2010 Sep 7;38(9):1522-31. Epub 2010 Jun 7.

Pharmacokinetics, Dynamics and Metabolism Department, Pfizer, Inc. St. Louis Laboratory, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.110.032581DOI Listing
September 2010
38 Reads
3 Citations
3.252 Impact Factor

Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1).

J Pharmacol Exp Ther 2010 Sep 2;334(3):936-44. Epub 2010 Jun 2.

Departments of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., St. Louis, Missouri, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.110.170753DOI Listing
September 2010
71 Reads
6 Citations
3.972 Impact Factor

Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters.

Mol Pharm 2010 Jun;7(3):630-41

Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research & Development, Pfizer Inc, Groton, Connecticut 06340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/mp9001574DOI Listing
June 2010
9 Reads
10 Citations
4.384 Impact Factor

Evaluation of drug transporter interactions in drug discovery and development.

Comb Chem High Throughput Screen 2010 Feb;13(2):112-34

Pfizer Global Research and Development, Department of Pharmacokinetics, Dynamics, and Metabolism, St Louis Laboratories, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138620710790596772DOI Listing
February 2010
40 Reads
3 Citations
1.222 Impact Factor

Pharmacokinetic and pharmacodynamic evaluation of the suitability of using fluticasone and an acute rat lung inflammation model to differentiate lung versus systemic efficacy.

J Pharm Sci 2009 Nov;98(11):4354-64

Global Research and Development, Pharmaceutical Research and Development, St. Louis Laboratories, Pfizer Inc., 700 Chesterfield Parkway N. T2F, Chesterfield, Missouri, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.21714DOI Listing
November 2009
36 Reads
3 Citations
2.590 Impact Factor

Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion.

Authors:
Yurong Lai

Expert Opin Drug Metab Toxicol 2009 Oct;5(10):1175-87

Pfizer Global Research & Development, Pfizer, Inc., Department of Pharmacokinetic, Dynamics, & Metabolism, St Louis Laboratory, 700 Chesterfield Parkway West, St Louis Chesterfield, MO 63017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425250903127234DOI Listing
October 2009
130 Reads
3 Citations
2.831 Impact Factor

Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

AAPS J 2009 Sep 3;11(3):406-13. Epub 2009 Jun 3.

St Louis Laboratories, Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-009-9117-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758110PMC
September 2009
10 Reads
1 Citation
3.800 Impact Factor

Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes.

Mol Pharm 2009 Jul-Aug;6(4):1180-9

Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research & Development, St. Louis Laboratories, St. Louis, Missouri, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/mp900044xDOI Listing
September 2009
58 Reads
16 Citations
4.384 Impact Factor

Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs.

Drug Metab Dispos 2009 Jul 16;37(7):1443-7. Epub 2009 Apr 16.

Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research and Development, St. Louis Laboratories, Pfizer Inc., St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.108.026245DOI Listing
July 2009
7 Reads
4 Citations
3.252 Impact Factor

Saturation of multidrug-resistant protein 2 (mrp2/abcc2)-mediated hepatobiliary secretion: nonlinear pharmacokinetics of a heterocyclic compound in rats after intravenous bolus administration.

Drug Metab Dispos 2009 Apr 12;37(4):841-6. Epub 2009 Jan 12.

Pharmacokinetic, Dynamics, and Metabolism, Pfizer, Inc., St. Louis Laboratory, 700 Chesterfield Parkway West, Chesterfield, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.108.024059DOI Listing
April 2009
28 Reads
4 Citations
3.252 Impact Factor

LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species.

Anal Chem 2009 Mar;81(6):2251-9

Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research and Development, St. Louis Laboratories, Pfizer Inc., St. Louis, Missouri 63017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ac8024009DOI Listing
March 2009
35 Reads
16 Citations
5.640 Impact Factor

Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery.

Nanoscale Res Lett 2009 Jan 6;4(3):254-261. Epub 2009 Jan 6.

Global Research and Development, Pharmaceutical Research and Development, St. Louis Laboratories, Pfizer Inc, 700 Chesterfield parkway N. T2F, Chesterfield, MO USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11671-008-9234-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2894320PMC
January 2009
61 Reads
1 Citation
2.780 Impact Factor

Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human.

Drug Metab Dispos 2009 Jan 2;37(1):66-73. Epub 2008 Oct 2.

Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc., St. Louis, Missouri, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.108.023234DOI Listing
January 2009
55 Reads
15 Citations
3.252 Impact Factor

Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry.

Anal Biochem 2008 Sep 27;380(2):211-22. Epub 2008 May 27.

Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc., St. Louis, MO 63017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2008.05.032DOI Listing
September 2008
74 Reads
11 Citations
2.220 Impact Factor

Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human.

Eur J Pharm Sci 2008 Sep 28;35(1-2):114-26. Epub 2008 Jun 28.

Department of Pharmacokinetics, Pfizer Global Research & Development, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejps.2008.06.008DOI Listing
September 2008
71 Reads
12 Citations
3.350 Impact Factor

In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta.

Am J Physiol Regul Integr Comp Physiol 2007 Nov 29;293(5):R1809-22. Epub 2007 Aug 29.

Dept. of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpregu.00293.2007DOI Listing
November 2007
40 Reads
21 Citations
3.110 Impact Factor

Enhanced production of p24 Gag protein in HIV-1-infected rat cells fused with uninfected human cells.

Exp Mol Pathol 2007 Aug 12;83(1):125-30. Epub 2007 Jan 12.

Department of Pathology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2006.11.003DOI Listing
August 2007
26 Reads
2 Citations
2.710 Impact Factor

Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles.

Drug Metab Dispos 2007 Jun 19;35(6):937-45. Epub 2007 Mar 19.

Pharmacokinetic, Dynamics, & Metabolism, Pfizer, Inc. St Louis Laboratory, Chesterfield, MO 63017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.106.013250DOI Listing
June 2007
10 Reads
3 Citations
3.252 Impact Factor

Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine.

J Biol Chem 2006 Jun 4;281(24):16700-6. Epub 2006 Apr 4.

Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M513825200DOI Listing
June 2006
17 Reads
22 Citations
4.573 Impact Factor

Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein.

J Pharmacol Exp Ther 2006 Mar 17;316(3):1202-9. Epub 2005 Nov 17.

Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.105.095406DOI Listing
March 2006
95 Reads
12 Citations
3.972 Impact Factor

Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively.

Am J Physiol Cell Physiol 2005 Jan 29;288(1):C39-45. Epub 2004 Sep 29.

Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpcell.00192.2004DOI Listing
January 2005
93 Reads
2 Citations
3.780 Impact Factor

Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs.

J Biol Chem 2004 Feb 7;279(6):4490-7. Epub 2003 Nov 7.

Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M307938200DOI Listing
February 2004
17 Reads
21 Citations
4.573 Impact Factor

Epstein-Barr virus infection of rat lymphocytes expressing human CD21 results in restricted latent viral gene expression and not in immunoblastic transformation.

J Med Virol 2003 May;70(1):126-30

Department of Tumor Virology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.10369DOI Listing
May 2003
8 Reads
2.350 Impact Factor

Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies.

J Biol Chem 2002 Oct 3;277(40):37711-7. Epub 2002 Jul 3.

Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M204986200DOI Listing
October 2002
29 Reads
14 Citations
4.573 Impact Factor

A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine.

Biochemistry 2002 Feb;41(5):1512-9

Department of Pharmaceutics and Department of Zoology, University of Washington, Seattle, Washington 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi015833wDOI Listing
February 2002
29 Reads
18 Citations
3.020 Impact Factor

Top co-authors

Jashvant D Unadkat
Jashvant D Unadkat

University of Washington

11
Na Li
Na Li

School of Environmental Science and Engineering

11
Emi Kimoto
Emi Kimoto

Pharmacokinetics Dynamics and Metabolism

10
Yi-An Bi
Yi-An Bi

Pharmacokinetics

10
Hong Shen
Hong Shen

Roche Innovation Center Shanghai

9
Punit Marathe
Punit Marathe

Pharmaceutical Candidate Optimization

8
Theunis C Goosen
Theunis C Goosen

Pfizer Inc.

8
Bo Feng
Bo Feng

Shanghai East Hospital

8
Xi Qiu
Xi Qiu

Departments of Metabolism and Pharmacokinetics (H.S.

7